anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adhesive capsulitis of the shoulder is a relatively common entity which is poorly understood and produces a significant amount of morbidity in afflicted patients. The natural history of adhesive capsulitis is only just beginning to be understood. It is a self-limiting disease, but may take 18 to 36 months to resolve. During that time, individuals can suffer a significant amount of pain and miss a large amount of work. Many surgeons have treated this process with early manipulation with the outcome never being reported in a prospective manner. Some authors have advocated conservative non-operative treatment, knowing the natural history in most of these shoulders will be near resolution. The primary purpose of this study is to examine in a prospective randomized manner the results of continuous non-operative management versus arthroscopic capsulectomy. This study will determine if operative intervention with an arthroscopic capsulectomy can shorten the natural history of adhesive capsulitis, and give comparable results with non-operative management at final follow-up of 2 years.

A second purpose of the study is to try and identify the mechanism(s) responsible for adhesive capsulitis. Recent research suggests that cytokines and connective tissue growth factor (CTGF) may be involved in the inflammatory and fibrotic processes. The second purpose of this study involves histological and immunohistochemical analysis of capsular and synovial tissue routinely removed during an arthroscopic capsulectomy. Tissue taken from subjects in the surgical treatment group will be compared to tissue from patients undergoing an arthroscopic capsulectomy for reasons other than adhesive capsulitis (control group). Location and concentration of CTGF will be compared between these groups. If levels of CTGF are elevated in the treatment group as hypothesized, development and testing of agents that specifically reduce the action of CTGF may be indicated. A specific agent blocking CTGF has been developed and is nearing clinical trials.
FIELD: chemistry. ^ SUBSTANCE: invention relates to novel crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride, hydrates and/or solvates (versions) thereof, for which characteristic powder diffraction patterns with radiation CuK1 are given, with characteristic peaks expressed in values of d (à). Said modifications can be used to treat neurological disorder. The invention also relates to pharmaceutical compositions (versions) which may additionally contain folate, separately or together with arginine in an effective amount. The folate is folic acid or tetrahydrofolate selected from tetrahydrofolic acid, 5,10-methylene-tetrahydrofolic acid, 10-formyl-tetrahydrofolic acid, 5-formyl-tetrahydrofolic acid or 5-methyl-tetrahydrofolic acid, or polyglutamate thereof or pharmaceutically acceptable salt thereof. The invention also relates to methods of producing (versions) said crystalline modifications. For example, the method of producing crystalline form A of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride involves dissolving (6R)-L-erythro-tetrahydrobiopterin dihydrochloride in water at ambient temperature, and (1) cooling the solution to a low temperature with solidification of the solution, and removing water at pressure ranging from 0.01 to 1 mbar, or (2) removing water from said aqueous solution by filtering and drying with evaporation of water, and extracting said crystalline form. ^ EFFECT: improved properties of compounds. ^ 42 cl, 18 tbl, 15 dwg, 6 ex
Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
PURPOSE:To obtain the titled impression material usable even when wetted with water, by adding a water-soluble or hardly water-soluble protein to a silicone impression material or further a hydrophilizing agent selected from hydrophilic silicone oils and nonionic surfactants thereto. CONSTITUTION:A dental silicone precise impression material which is a condensation or addition polymerization type room temperature curing dental silicone impression material obtained by adding 0.1-10.0wt% water-soluble or hardly water-soluble protein, e.g. albumin, gelatin, casein, albumin tannate, etc., or further adding 0.05-5.0wt% hydrophilizing agent, i.e. one or two or more selected from hydrophilic silicone oils, e.g. polyether-modified silicone oil, etc., nonionic surfactants, e.g. polyoxyethylene alkyl ether, etc., Precise impression can be obtained even when the interior of the oral cavity is wetted in obtaining the impression.
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are among the leading causes of mortality worldwide. Cigarette smoking is among the main aetiologic factors for both ailments. These diseases share common pathogenetic mechanisms including inflammation, oxidative stress, and tissue remodelling. Current therapeutic approaches are limited by low efficacy and adverse effects. Consequentially, LC has a 5-year survival of < 20%, while COPD is incurable, underlining the necessity for innovative treatment strategies. Two promising emerging classes of therapy against these diseases include plant-derived molecules (phytoceuticals) and nucleic acid-based therapies. The clinical application of both is limited by issues including poor solubility, poor permeability, and, in the case of nucleic acids, susceptibility to enzymatic degradation, large size, and electrostatic charge density. Nanoparticle-based advanced drug delivery systems are currently being explored as flexible systems allowing to overcome these limitations. In this review, an updated summary of the most recent studies using nanoparticle-based advanced drug delivery systems to improve the delivery of nucleic acids and phytoceuticals for the treatment of LC and COPD is provided. This review highlights the enormous relevance of these delivery systems as tools that are set to facilitate the clinical application of novel categories of therapeutics with poor pharmacokinetic properties.
The invention relates to a cholagogic tea which is prepared by the following method: 1-10% of white tea, 2-5% of dandelion, 1-8% of poria cocos, 2-5% of radix puerariae, 3-6% of platycodon grandiflorum, 4-8% of raw malt, 3-6% of rose mallow, 1-5% of bamboo leaves, 1-7% of seville orange flowers, 1-5% of hovenia dulcis thunb and 1-5% of wolfberry fruit are added into the balance water, dried at 70-80 ℃, mixed, crushed, sieved by a 10-30-mesh sieve, fried at 95-100 ℃ for 5-7 minutes, packaged by a triangular bag or a tea filter paper bag, 5-7 g/bag, and then sterilized by 400W ultrasonic wave of 200-charge tea for 3-5 minutes to obtain the cholagogic tea. The invention also provides application of the cholagogic tea. The invention has the advantages that: the compatibility principle of 'monarch, minister, assistant and guide' is met among the raw material medicines. The composition has reasonable and delicate compatibility, thus achieving good clinical curative effect. The invention has the advantages of homology of medicine and food, safety and reliability. The optimal proportion among the raw material medicines is obtained through experimental screening, and the method has the advantage of remarkable effect.
Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
Disclosed is a method for preparing an aqueous phytosphingosine solution containing as much as 5-10 weight % of phytosphingosine without using any solvents other than water. A high content of phytosphingosine is dissolved in water and lactic acid with the help of a willow bark extract. In addition to being clear, the aqueous phytosphingosine solution is able to recover damaged skin with activity against bacteria and inflammation. Also, when being applied for cosmetics, the aqueous phytosphingosine solution allows them to contain as much as 1-2 weight % of phytosphingosine by virtue of its high content of phytosphingosine. Further, the phytosphingosine solution is greatly improved in compatibility with cosmetic components so that it can be readily applied for aqueous cosmetics such as skin lotions, essence lotions, aqueous pack products, body essence compositions, etc., for which phytosphingosine has not yet been applied, thus far. Thus, the phytosphingosine solution of the present invention gives a great contribution to the functional improvement of aqueous cosmetics.
PURPOSE: A display apparatus and a display method are provided to easily determine an exact photographing position of a patient and a patient posture at a photographing process by displaying descriptive data of a medical image on a proper location in a mimetic diagram of a human body. CONSTITUTION: A display device(1) comprises a controller(10), a monitor(104), a mouse(105), and a keyboard(106). The controller comprises a central processing unit(100), a main memory(101), a magnetic disc(102), and a display memory(103). The central processing unit executes all kinds of controls like communication control of a medical image database(2) and the control of the image display apparatus to execute a program saved in the main memory. The central processing unit controls the operation of each element of the display device. The magnetic disc stores an operating system, a device drive of peripheral devices, and all kinds of application software including a program for diagnosis support processing. The display memory temporarily stores display data for a monitor.
Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
OBJECTIVES: Medical cannabinoids have become increasingly popular over the last decade. Preclinical trials suggest cannabinoids, for example, cannabidiol (CBD), may provide an anticancer effect; however, good-quality clinical information supporting this is lacking. We assessed the effect of CBD treatment on disease progression and survival in patients enrolled in a study of CBD versus placebo for symptom management in patients with advanced cancer (MEDCAN-1).
METHODS: We reviewed the clinical records of all patients enrolled in the MEDCAN-1 Study (CBD vs placebo) at days 14, 28 and 56 of study follow-up, for evidence of disease progression. The proportion of participants with disease progression by treatment arm at each time point was compared, as was survival between both groups from study entry to the censor date (end of study period) and the effect of treatment arm and disease progression status on survival.
RESULTS: Of the 135 patient records assessed, 128 were included in the final analysis. 36% (n=46) had progressive disease documented at day 28, rising to 49.2% (n=63) by day 56. No significant difference in disease progression was noted between the two groups at days 14 (p=0.33), 28 (p=0.67) or 56 (p=0.50). There was no difference in survival between both groups from study entry to censor date (p=0.38). Disease progression at day 14 was highly predictive of mortality (p<0.001).
CONCLUSIONS: In this substudy analysis, treatment with CBD oil did not affect disease progression or survival over the course of 56 days in patients with advanced cancer.
Disclosed are a preparation method and the applications of a polysaccharide selenous acid ester, belonging to the polysaccharide selenide technical field. The invention is characterized in that the polysaccharide selenous acid ester is made essentially by reaction between polysaccharide or carbohydrate complex and selenide reagent which is selenium Oxyhalide or the compound contains the selenium Oxyhalide. Feeding molar ratio of the selenide reagent and hydroxyl groups in the polysaccharide is 1:0.1-20. The invention also comprises the applications of the polysaccharide selenous acid ester in preparing anticancer drug and ant-oxidation drug. The polysaccharide selenous acid ester is produced by the reaction between the selenium reagent and the hydroxyl groups in sugar units, but not by selenite radicals substituting sulfate groups of the polysaccharide sulfate. The yield and the quality of the product are both higher than that of the products produced by other methods, and the selenium content is much higher than that of the products produced by the present technique.
BACKGROUND: Metastasis has been a cause of the poor prognosis and cancer relapse of triple-negative breast cancer (TNBC) patients. The metastatic nature of TNBC is contributed by the breast cancer stem cells (CSCs) which have been implicated in tumorigenesis. Higher expression of epidermal growth factor receptor (EGFR) in breast CSCs has been used as a molecular target for breast cancer therapeutics. Thus, it necessitates the design and generation of efficacious EGFR inhibitors to target the downstream signaling associated with the cellular proliferation and tumorigenesis of breast cancer.
AIM: To generate efficacious EGFR inhibitors that can potentiate the chemotherapeutic-mediated mitigation of breast cancer tumorigenesis.
METHODS AND RESULTS: We identified small molecule EGFR inhibitors using molecular docking studies. In-vitro screening of the compounds was undertaken to identify the cytotoxicity profile of the small-molecule EGFR inhibitors followed by evaluation of the non-cytotoxic compounds in modulating the doxorubicin-induced migration, in-vitro tumorigenesis potential, and their effect on the pro-apoptotic genes' and protein markers' expression in TNBC cells. Compound 1e potentiated the doxorubicin-mediated inhibitory effect on proliferation, migration, in-vitro tumorigenesis capacity, and induction of apoptosis in MDA-MB-231 cells, and in the sorted CD24+-breast cancer cells and CD24-/CD44+-breast CSC populations. Orthotopic xenotransplantation of the breast CSCs-induced tumors in C57BL/6J mice was significantly inhibited by the low dose of Doxorubicin in the presence of compound 1e as depicted by molecular and immunohistochemical analysis.
CONCLUSION: Thus, the study suggests that EGFR inhibition-mediated sensitization of the aggressive and metastatic breast CSCs in TNBCs toward chemotherapeutics may reduce the relapse of the disease.
Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
With the spread of artemisinin resistance throughout Southeast Asia and now in Africa, the antimalarial drug pyronaridine is likely to become an increasingly important component of new antimalarial drug regimens. However, the antimalarial activity of pyronaridine in humans has not been completely characterised. This volunteer infection study aimed to determine the pharmacokinetic/pharmacodynamic (PK/PD) relationship of pyronaridine in malaria naïve adults. Volunteers were inoculated with Plasmodium falciparum-infected erythrocytes on day 0 and administered different single oral doses of pyronaridine on day 8. Parasitaemia and concentrations of pyronaridine were measured and standard safety assessments performed. Curative artemether-lumefantrine therapy was administered if parasite regrowth occurred, or on day 47 ± 2. Outcomes were parasite clearance kinetics, PK and PK/PD parameters from modelling. Ten participants were inoculated and administered 360 mg (n = 4), 540 mg (n = 4) or 720 mg (n = 1) pyronaridine. One participant was withdrawn without receiving pyronaridine. The time to maximum pyronaridine concentration was 1-2 h, the elimination half-life was 8-9 d, and the parasite clearance half-life was approximately 5 h. Parasite regrowth occurred with 360 mg (4/4 participants) and 540 mg (2/4 participants). Key efficacy parameters including the minimum inhibitory concentration (5.5 ng/mL) and minimum parasiticidal concentration leading to 90% of maximum effect (MPC90: 8 ng/mL) were derived from the PK/PD model. Adverse events considered related to pyronaridine were predominantly mild to moderate gastrointestinal symptoms. There were no serious adverse events. Data obtained in this study will support the use of pyronaridine in new antimalarial combination therapies by informing partner drug selection and dosing considerations.
Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
1. Technical Result Increase in therapeutical effectiveness.         2. Essence Isatin or isatinoxime derivatives of the formula (1)   ( the values R4, R5, z, x, y and Q are disclosed in the description) and method for production, which comprises interaction of compounds of the formula (1) with hydroxilamines in which Q-0 or its reaction capable derivatives. Pharmaceutical composition on its basis having the activity connected with blockade of glutamine or aspargine acids.         3. Field of Application Pharmaco-chemistry and medicine.
Patients will receive the best available standard of care. In control group, 3 doses of equal volume of normal saline will be administered as an IV bolus over 1 minutes every 3 hours ± 1 hour on day 1, the same dosing regimen will be repeated every month for 6 months post randomization.
PURPOSE: Head and neck emergencies in children are frequent cause of visits to the hospital. Imaging plays a critical role in the management of these patients. This review article aims to familiarize radiologists with the common clinical presentations encountered, imaging characteristics of nontraumatic pediatric head and neck emergencies, and improve their ability to recognize associated complications as well as be aware of common mimics.
METHODS: We researched our database for commonly encountered nontraumatic head and neck emergencies in children. A literature search was done to compare and complete the list of conditions to be discussed in this review.
RESULTS: The review was organized according to anatomical location of the emergent condition. Relevant anatomy has been discussed along with clinical presentation, imaging characteristics and complications. We have presented common mimics with each set of disorders. Key imaging characteristics have been delineated using radiology images.
CONCLUSION: Familiarity with the known complications of head and neck emergencies allows the radiologist to actively search for such findings, encourage early institution of appropriate therapy, and improve outcomes.
The invention relates to a calculus-decomposing and calculus-expelling pill for treating lithiasis. Particularly, the pill has the effects of inducing diuresis to expel the calculus and clearing heat and removing toxicity, and can be used for treating urinary calculus and hepatolithiasis. The urinary calculus and the hepatolithiasis have common characteristics of damp, heat and blood stasis in etiology and pathogenesis, and both the urinary calculus and the hepatolithiasis are preferable to take descending as harmonious states, so that one formula can treat the two diseases. However, for the difference between the urinary calculus and the hepatolithiasis, different taking methods are adopted, so that the diseases can be treated rapidly and safely. The pill employs the compatibility of three traditional Chinese medicines of inner membrane of chicken gizzard, mirabilite and amber, and simultaneously herba lysimachiae is cooperated for taking frequently instead of tea. For the hepatolithiasis, herba glechomae is used; and for the urinary calculus, lawn pennywort herb is used. The pill is taken frequently instead of tea with no limit of times, preferably as more as possible. The pill is few but good in medicines, has specific effects and great power, and can dissipate mass and eliminate stagnation, relieve stranguria and promote diuresis. Besides, the pill is taken in herba lysimachiae water form, and is fast and safe in decomposing calculus and expelling the calculus, without any toxic or side effect.
While the advent of highly active antiretroviral therapy (HAART) has contributed to the increasing control of HIV infection and viral replication, ultimate control of HIV infection will require the development of effective HIV-specific immunity in HIV infected individuals. Therapeutic vaccination within the earliest weeks following acute or recent HIV infection may increase the immune system's response to HIV. This study will determine whether MRKAd5 HIV-1 gag/pol/nef vaccine followed by treatment interruption can maintain viral suppression in patients with acute or recent HIV infection.

The interventional part of the study will last 102 weeks. Participants will be randomly assigned to receive either MRKAd5 HIV-1 gag/pol/nef or placebo vaccine at baseline and Weeks 4 and 26. Participants must remain on HAART from study entry until Week 38. Participants whose HIV viral load rebounds two times or more above 500 copies/ml by Weeks 39 to 41 will not enter Step 2 of the study. Participants whose viral load drops to 500 copies/ml or less by Weeks 39 to 41 will enter Step 2, where they will discontinue HAART for 24 weeks. Participants in Step 2 will have plasma HIV viral loads measured every 2 weeks for the first 4 weeks and weekly for the next 3 weeks. Study participants will continue in Step 2 until they experience virologic and immunologic failure or they need to restart HAART for another reason; they will then enter Step 3, where they will reinitiate HAART. Step 3 participants will continue on HAART until Week 102. A long-term safety follow-up period will occur from Weeks 103 to 240.

Timing of the study visits will be determined by which steps a participant enters. A physical exam and blood and urine collection will occur at most study visits throughout the study until Week 102. Follow-up phone calls to study participants will occur every 6 months from Week 102 until Week 240 to collect long-term safety data, including clinical status, CD4 count, and medication history. During the long-term safety follow-up, participants will also have study visits every 6 months. Visits will include medical and medication history.